Form 4: Teva Pharmaceutical Industries Director Tal Zvi Zaks Reports Acquisition of Restricted Share Units

Director Tal Zvi Zaks reports acquisition of 9,632 restricted share units in Teva Pharmaceutical Industries, vesting on June 6, 2025.

Summary

• Tal Zvi Zaks, a director of Teva Pharmaceutical Industries Ltd, filed a Form 4 on June 10, 2024, reporting a transaction.
• On June 6, 2024, Zaks acquired 9,632 restricted share units (RSUs).
• These RSUs represent a contingent right to receive one ordinary share or the cash value of one ordinary share at settlement, as determined by the Human Resources and Compensation Committee.
• The RSUs vest on June 6, 2025.
• Following the reported transaction, Zaks directly owns 9,632 derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The acquisition of shares by a director is generally a positive sign, indicating confidence in the company's future. However, it's a routine transaction related to compensation.

Positives

• The acquisition of restricted share units by a director signals confidence in the company's future performance.

Future Outlook

The restricted share units vest in one year, aligning the director's interests with the company's performance over that period.

Industry Context

Insider transactions are closely monitored as indicators of management's confidence in the company's prospects within the pharmaceutical industry.

Stakeholder Impact

• The acquisition of restricted share units by a director can positively influence shareholder sentiment.

Key Dates